Background/aim: Primary ocular adnexal lymphomas pose a diagnostic challenge for physicians due to their nonspecific symptom presentation and resemblance to other periorbital masses, such as skin and soft tissue infections. Early diagnosis and appropriate management are crucial for optimizing outcomes and coordination of therapy.
Case Report: We present a case of a 67-year-old male with a history of infraorbital trauma, initially managed as a soft tissue infection, which was later revealed to be a large B-cell lymphoma. Despite multiple specialty evaluations, including dermatology, ophthalmology, plastic surgery, and ENT, among others, diagnosis was delayed, leading to worsening symptoms and vision impairment.
Conclusion: This case highlights the importance of considering ocular adnexal lymphomas in the differential diagnosis of periorbital masses and the need for interdisciplinary collaboration for timely recognition and treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871858 | PMC |
| http://dx.doi.org/10.21873/cdp.10437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bispecific antibody therapy for lymphoma.
Best Pract Res Clin Haematol
December 2024
330 Brookline Ave, Boston, MA, 02215, USA. Electronic address:
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL.
View Article and Find Full Text PDFCARs for lymphoma.
Best Pract Res Clin Haematol
December 2024
Department of Medicine, Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized treatment options for B-cell Non-Hodgkin Lymphoma (NHL). CD19-targeting CAR-T cell therapy is approved for treatment in Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR-T cells demonstrate robust and durable responses even in heavily pretreated patients.
View Article and Find Full Text PDFCombination therapy using parthenolide and doxorubicin induces apoptosis in Raji cells: insights into miR-27b and signaling pathway alterations.
Med Oncol
March 2025
Division of Hematology and Blood Banking, Department of Laboratory Science, School of Paramedical Science, Shiraz University of Medical Science, Shiraz, Iran.
Burkitt lymphoma, a highly aggressive form of non-Hodgkin lymphoma, have significant treatment challenges, such as chemotherapy-related toxicity and the risk of relapse, especially in older adults. Treatment of Raji cells, a Burkitt lymphoma cell line, with parthenolide in combination to doxorubicin may enhance therapeutic efficacy. This study aimed to evaluate cell viability and apoptosis following treatment with these agents, and to investigate the underlying molecular mechanisms involving miR-27b and the MET/PI3K/AKT signaling pathway.
View Article and Find Full Text PDFContinuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.
Cancer Biol Med
March 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Objective: Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of R-DA-EDOCH immunochemotherapy in treating aggressive B-cell lymphomas, we designed a prospective, phase 3 trial to explore the efficacy and safety of alternating R-DA-EDOCH/R-DHAP induction therapy for young patients with newly diagnosed MCL. The primary endpoint was the complete remission rate (CRR) at the end of induction (EOI).
View Article and Find Full Text PDFExpression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy.
Am J Clin Pathol
March 2025
Department of Pathology, Stanford University, Stanford, CA, United States.
Objectives: Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Methods: This study evaluates CD47 expression in a wide range of hematolymphoid neoplasms using immunohistochemistry on 834 cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!